At a Glance
| Item | Detail |
|---|---|
| CDL / PMB Status | Chronic Disease List (CDL) condition |
| ICD-10 Codes | G40.0–G41.9 |
| SA Prevalence | ~1.5% (~600,000–900,000 people) |
| Annual Cost (managed) | R6,000–R15,000 |
| Annual Cost (refractory/specialist) | R15,000–R36,000 |
| Biologic Risk | No |
| Gap Cover Relevance | Medium |
What is Epilepsy?
Epilepsy is a chronic neurological disorder characterised by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. A single seizure does not constitute epilepsy — the diagnosis requires two or more unprovoked seizures, or one seizure with a high probability of recurrence.
South Africa has a higher epilepsy prevalence than most high-income countries, driven by conditions that cause brain injury: neurocysticercosis (a parasitic infection caused by pork tapeworm larvae — common in rural SA), HIV-associated neurological disease, perinatal hypoxia (oxygen deprivation during birth), and traumatic brain injury. Approximately 600,000–900,000 South Africans live with epilepsy.
Epilepsy is a Chronic Disease List (CDL) condition. All registered open medical aid schemes must fund CDL-level treatment for members who register the condition.
Types of Epilepsy and Seizures
Focal (partial) seizures originate in one part of the brain and account for ~60% of SA cases: - Focal aware (consciousness preserved — formerly "simple partial") - Focal impaired awareness (consciousness affected — formerly "complex partial") - May spread to generalised tonic-clonic seizure (secondary generalisation)
Generalised seizures involve both hemispheres simultaneously: - Generalised tonic-clonic (GTC / "grand mal"): rhythmic convulsions; post-ictal confusion - Absence seizures: brief lapses of awareness; common in childhood - Myoclonic, atonic ("drop attacks"), and tonic seizures
Status epilepticus is a medical emergency: a seizure lasting more than 5 minutes, or multiple seizures without full recovery between them. Requires immediate emergency treatment to prevent permanent brain damage.
How is Epilepsy Treated?
Anti-epileptic drugs (AEDs) are the mainstay of treatment. The goal is complete seizure freedom with minimal side effects. Approximately 70% of epilepsy patients achieve seizure control on medication; ~30% have drug-resistant (refractory) epilepsy requiring specialist management.
First-line treatment by seizure type:
| Seizure Type | First-Choice AED |
|---|---|
| Generalised tonic-clonic | Sodium valproate, lamotrigine |
| Focal seizures | Carbamazepine, oxcarbazepine, lamotrigine, levetiracetam |
| Absence | Sodium valproate, ethosuximide |
| Juvenile myoclonic epilepsy | Sodium valproate, levetiracetam |
Second-line / adjunctive agents: Levetiracetam, topiramate, zonisamide, lacosamide, pregabalin.
Surgical evaluation: Patients with drug-resistant focal epilepsy should be referred to a specialist epilepsy centre for surgical evaluation. Temporal lobectomy can be curative for temporal lobe epilepsy with a defined focus.
Medication Costs (2025/2026 — Prices Estimated; SAHPRA SEP Verification Pending)
| Medication | Class | Monthly Cost | Annual Cost |
|---|---|---|---|
| Sodium valproate 200mg (generic) | First-line — generalised | ~R180 | ~R2,160 |
| Carbamazepine 200mg (generic) | First-line — focal | ~R120 | ~R1,440 |
| Lamotrigine 100mg (generic) | Adjunct / second-line | ~R350 | ~R4,200 |
| Levetiracetam 500mg (generic) | Adjunct / second-line | ~R700 | ~R8,400 |
| Oxcarbazepine 600mg (generic) | Alternative focal | ~R500 | ~R6,000 |
| Phenytoin 100mg (generic) | Older agent | ~R80 | ~R960 |
All prices estimated. SAHPRA SEP verification flagged.
Annual Cost Breakdown
| Category | Low Estimate | High Estimate |
|---|---|---|
| GP visits (4 per year) | R3,200 | R3,200 |
| Neurologist visits (2 per year) | R3,000 | R6,000 |
| Chronic medication (AED) | R1,440 | R8,400 |
| Monitoring (drug levels, FBC, LFTs, EEG PRN) | R2,000 | R4,000 |
| Hospital (status epilepticus ICU — low probability) | R0 | R45,000 |
| Total estimated annual cost | R9,640 | R36,000+ |
Medical Aid Coverage
Epilepsy is a CDL condition. Registered open schemes must fund: - Anti-epileptic drugs (AEDs) at CDL formulary level - GP and neurology consultations - Monitoring blood tests (drug levels, FBC, LFTs) - EEG (as clinically indicated) - Emergency treatment for status epilepticus (PMB emergency)
Formulary consideration: Most scheme CDL formularies cover sodium valproate, carbamazepine, and phenytoin. Levetiracetam and lamotrigine — which have better tolerability and safety profiles — may require pre-authorisation or exceptional needs motivation on some plans. Check your specific scheme's CDL AED formulary.
Specialist shortfall: Neurologists frequently bill above scheme rate. The gap between what a private neurologist charges and what the scheme pays is the primary gap cover use case for epilepsy.
Gap Cover Relevance
Medium relevance overall. The two scenarios where gap cover matters:
- Neurologist shortfall: Private neurology appointments frequently exceed scheme rate. Gap cover pays the difference. Expect R600–R1,500 per consultation shortfall.
- Status epilepticus ICU admission: A major epilepsy emergency requiring ICU care. Neurologist + intensivist shortfalls, HDU/ICU billing above scheme rate. Episode cost R30,000–R60,000; gap cover significantly reduces OOP. Note the gap cover annual overall payment limit of approximately R220,000 — unlikely to be reached for epilepsy in most cases.
Key Considerations for Plan Selection
- AED formulary breadth: Ensure your scheme's CDL formulary includes lamotrigine and levetiracetam — not just valproate and carbamazepine.
- Neurology access: Is a neurologist required? For well-controlled epilepsy, GP management with periodic neurology review is appropriate. For refractory epilepsy, specialist access is essential.
- Emergency cover: Status epilepticus is a PMB emergency — all schemes must cover it. But specialist shortfall is your financial risk.
- Women of childbearing potential: Sodium valproate is teratogenic. Planning pregnancy with epilepsy requires specialist neurology review and possibly medication change — this process involves GP and specialist consultations that scheme coverage affects.
Sources
- South African Epilepsy Society (SAES) — Management Guidelines 2023
- CMS PMB Regulation 8 — CDL: Epilepsy
- Shorvon SD. Status Epilepticus. Oxford University Press, 2011.
- SAHPRA SEP database — prices estimated; verification pending.
To see what your own plan pays, check your cover with AURA →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).